Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, March 30 '25)

Image
By G.M.

 


    Ann Intern Med

  1. GRANWEHR BP
    CBT and rehabilitation improved long COVID symptoms.
    Ann Intern Med. 2025;178:JC28.
    PubMed         Abstract available


    BMJ

  2. WISE J
    Covid-19: Inquiry hears of doctors' lack of confidence in PPE as ministers defend VIP lane.
    BMJ. 2025;388:r584.
    PubMed        


    Clin Infect Dis

  3. ALLAN-BLITZ LT, Klausner JD
    Shifting the Focus in Acute SARS-CoV-2 Management to Include Prevention of Long-COVID.
    Clin Infect Dis. 2025 Mar 26:ciaf158. doi: 10.1093.
    PubMed        


    Emerg Infect Dis

  4. SANDER B, Mishra S, Swayze S, Sahakyan Y, et al
    Population-Based Matched Cohort Study of COVID-19 Healthcare Costs, Ontario, Canada.
    Emerg Infect Dis. 2025;31:710-719.
    PubMed         Abstract available


    Intensive Care Med

  5. BIHLMAIER K, Willam C, Herbst L, Hackstein H, et al
    Rapid clinical effects of convalescent plasma therapy in severe COVID-19 acute respiratory distress syndrome (ARDS).
    Intensive Care Med. 2025 Mar 26. doi: 10.1007/s00134-025-07863.
    PubMed        


    J Infect

  6. JIN R, Qin T, Li P, Yuan J, et al
    Increased Circulation of Adenovirus in China During 2023-2024: Association with an Increased Prevalence of Species B and School-Associated Transmission.
    J Infect. 2025 Mar 21:106475. doi: 10.1016/j.jinf.2025.106475.
    PubMed         Abstract available

  7. CARSTENS G, Kozanli E, Bulsink K, McDonald S, et al
    Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands.
    J Infect. 2025 Mar 21:106474. doi: 10.1016/j.jinf.2025.106474.
    PubMed         Abstract available

  8. BING J, Huang Y, Du H, Guo P, et al
    Rapid spread of Candida auris in China after COVID-19.
    J Infect. 2025 Mar 21:106476. doi: 10.1016/j.jinf.2025.106476.
    PubMed        


    J Med Virol

  9. LARSEN TG, Ginty JR, Jessen R, Nielsen RB, et al
    Virus Monitoring in Denmark: A Community-Based Self-Sampling System to Surveil Respiratory Viruses and Associated Symptoms.
    J Med Virol. 2025;97:e70293.
    PubMed         Abstract available

  10. TACHIKAWA J, Aizawa Y, Watanabe K, Haino K, et al
    Sustained Maternal Antibodies Against Parechovirus-A3 During the Coronavirus Disease 2019 Pandemic.
    J Med Virol. 2025;97:e70313.
    PubMed         Abstract available


    J Virol

  11. NOETTGER S, Zech F, Nchioua R, Pastorio C, et al
    Role of N-linked glycosylation sites in human ACE2 in SARS-CoV-2 and hCoV-NL63 infection.
    J Virol. 2025 Mar 28:e0220224. doi: 10.1128/jvi.02202.
    PubMed         Abstract available

  12. JANA ID, Kanjo K, Roy S, Bhasin M, et al
    Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.
    J Virol. 2025 Mar 26:e0005125. doi: 10.1128/jvi.00051.
    PubMed         Abstract available

  13. ZHANG S, Cao Y, Huang Y, Zhang X, et al
    Abortive PDCoV infection triggers Wnt/beta-catenin pathway activation, enhancing intestinal stem cell self-renewal and promoting chicken resistance.
    J Virol. 2025 Mar 26:e0013725. doi: 10.1128/jvi.00137.
    PubMed         Abstract available

  14. LI P, Faraone JN, Hsu CC, Chamblee M, et al
    Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.
    J Virol. 2025 Mar 26:e0024225. doi: 10.1128/jvi.00242.
    PubMed         Abstract available

  15. JOHN K, Huntress I, Smith E, Chou H, et al
    Human long noncoding RNA VILMIR is induced by major respiratory viral infections and modulates the host interferon response.
    J Virol. 2025 Mar 25:e0014125. doi: 10.1128/jvi.00141.
    PubMed         Abstract available

  16. DADONAITE B, Burrell AR, Logue J, Chu HY, et al
    SARS-CoV-2 neutralizing antibody specificities differ dramatically between recently infected infants and immune-imprinted individuals.
    J Virol. 2025 Mar 25:e0010925. doi: 10.1128/jvi.00109.
    PubMed         Abstract available


    JAMA

  17. HANLON P, Butterly E, Wei L, Wightman H, et al
    Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.
    JAMA. 2025 Feb 3:e2427402. doi: 10.1001/jama.2024.27402.
    PubMed         Abstract available


    Nat Ment Health

  18. ATLAS LY, Farmer C, Shaw JS, Gibbons A, et al
    Dynamic effects of psychiatric vulnerability, loneliness and isolation on distress during the first year of the COVID-19 pandemic.
    Nat Ment Health. 2025;3:199-211.
    PubMed         Abstract available


    Nature

  19. KOZLOV M
    Exclusive: NIH to cut grants for COVID research, documents reveal.
    Nature. 2025 Mar 26. doi: 10.1038/d41586-025-00954.
    PubMed        

  20. VAN DAMME E, Abeywickrema P, Yin Y, Xie J, et al
    A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein.
    Nature. 2025 Mar 26. doi: 10.1038/s41586-025-08651.
    PubMed         Abstract available

  21. WANG X, Huang Z, Xing L, Shang L, et al
    STING agonist-based ER-targeting molecules boost antigen cross-presentation.
    Nature. 2025 Mar 26. doi: 10.1038/s41586-025-08758.
    PubMed         Abstract available

  22. LAPORTE M, Jochmans D, Bardiot D, Desmarets L, et al
    A coronavirus assembly inhibitor that targets the viral membrane protein.
    Nature. 2025 Mar 26. doi: 10.1038/s41586-025-08773.
    PubMed         Abstract available


    Science

  23. COHEN J
    U.S. cuts hamper disease surveillance worldwide.
    Science. 2025;387:1336-1337.
    PubMed         Abstract available


    Travel Med Infect Dis

  24. PFAAR H, Lopez-Medina E, Escudero I, Hutagalung Y, et al
    Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific.
    Travel Med Infect Dis. 2025 Mar 20:102840. doi: 10.1016/j.tmaid.2025.102840.
    PubMed         Abstract available

  25. BOGACKA A, Wroczynska A, Grzybek M
    Polish travellers on the move: a study of knowledge of travel health and associated practices among Polish travellers abroad.
    Travel Med Infect Dis. 2025 Mar 20:102842. doi: 10.1016/j.tmaid.2025.102842.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »